With the introduction of direct antiviral agents (DAAs) for hepatitis C, the hepatitis C virus has ushered in the era of eradication. Anti-hepatitis B virus drugs have been widely used in the clinic but currently can only achieve a sustained level of suppression, are there any DAAs against hepatitis B virus that we should expect? We know that the root cause of hepatitis B virus is difficult to eradicate is the synthesis of hepatitis B covalent closed-loop DNA (cccDNA), Professor Stephan Urban of the University of Heidelberg, Germany, at the recently concluded APASL 2017 conference in Shanghai, proposed a “suppressor of virus entry/gene expression/protein release “-MyrcludexB, a viral envelope peptide blocking the cccDNA receptor, which is a very effective invasion blocker. The drug has now progressed from the academic theory stage to clinical trials, and a phase II clinical trial of MyrcludexB for hepatitis B was reported at the annual meeting of the AASLD in the USA. There are also new capsid and nucleocapsid inhibitors with different modes of action that block capsid assembly, which have been shown to reduce not only viral DNA in the patient’s blood but also viral RNA in the serum; because it has a different mechanism of action than nucleoside (acid) analogs (NA), it is possible that it can be used in combination with NA to treat hepatitis B. For example, ARC-520 uses Arrowhead’s unique dynamic polyconjugates delivery system, which is based on the principle that the expression of certain proteins of HBV is blocked by the action of RNA, resulting in the inability of the virus to proliferate, and then the remaining virus is cleared by the human immune system to achieve an immunoclean state, characterized by the serological conversion of HBsAg. The immunoclean state is characterized by the serological conversion of HBsAg. The published results of clinical trial IIa showed that the dose of 3 mg/kg administered as a single dose of HBsAg reduced serum HBsAg by 81% to 96% after 29 d, and the reduction remained statistically significant until 43-57 d. In April 2015, the FDA approved the continuation of a Phase IIb clinical trial of this drug (called Heparc-2004) to examine its clinical efficacy at multiple doses. Currently, Arrowhead has three RNAi drugs in clinical development and the ARC-520 program is advancing more successfully. These drugs offer new hope for hepatitis B patients. In addition, combination therapy (cocktail therapy) for hepatitis B is also a trend, which is currently mostly between nucleoside (acid) analogs or in combination with IFNs, but more drug combinations based on different mechanisms are expected to emerge in the future.